Icon's 5.85% Surge Boosted by Gene Therapy Milestones and Strong Institutional Buying Trading Volume Ranks 457th at $240M

On September 11, 2025, , ranking 457th in market activity. The biotechnology firm's shares gained momentum amid renewed focus on its pipeline advancements and regulatory updates. Recent developments highlighted its strategic collaborations in gene therapy and a key clinical trial milestone announcement, both of which have historically driven investor interest.

Analysts noted that Icon's performance correlated with increased participation in biotech sectors following macroeconomic signals suggesting potential easing of interest rate pressures. The stock's technical indicators showed improved short-term momentum, . Institutional buying patterns observed in pre-market sessions further reinforced the upward trajectory.

Market participants emphasized that Icon's valuation metrics remain attractive relative to sector peers, . Recent investor sentiment surveys indicated heightened confidence in the company's ability to execute its R&D roadmap, particularly in its oncology and rare disease segments.

To run this back-test accurately I need to pin down a few practical details: 1. Market universe • Do you want all U.S. listed common stocks (NYSE + NASDAQ + NYSE Arca) as the selection pool, or a different universe? 2. Weighting method • Should the 500 chosen names each day be held in equal weights, or proportionally to their dollar volume? 3. Ranking logic • Should the ranking be based on the current day’s volume (buy at that day’s close, sell at the next day’s close), or yesterday’s volume (buy at today’s open, sell at tomorrow’s open/close)? 4. Price points for entry/exit • Open-to-open, close-to-close, or another convention? With these four points confirmed I can lay out the data-gathering plan and launch the back-test.